Show simple item record

dc.creatorTrpković, Andreja
dc.creatorResanović, Ivana
dc.creatorStanimirović, Julijana
dc.creatorRadak, Đorđe J.
dc.creatorMousa, Shaker A.
dc.creatorCenic-Milosevic, Desanka
dc.creatorJevremovic, Danimir
dc.creatorIsenović, Esma R.
dc.date.accessioned2018-03-01T16:15:49Z
dc.date.available2018-03-01T16:15:49Z
dc.date.issued2015
dc.identifier.issn1040-8363
dc.identifier.issn1549-781X
dc.identifier.urihttp://vinar.vin.bg.ac.rs/handle/123456789/635
dc.description.abstractAtherosclerosis is a life-long illness that begins with risk factors, which in turn contribute to the development of subclinical disease, followed by the establishment of overt cardiovascular disease (CVD). Thrombotic-occlusive complications of atherosclerosis are among the most widespread and costly health problems. Oxidized low-density lipoprotein (OxLDL) plays an important role in atherogenesis by promoting an inflammatory environment and lipid deposition in the arterial wall. As cardiovascular events occur in individuals without common risk factors, there is a need for additional tools that may help in CVD risk assessment and management. The use of biomarkers has improved diagnostic, therapeutic and prognostic outcome in cardiovascular medicine. This review elaborates on the value of circulating OxLDL as a biomarker of CVD. Three enzyme-linked immunosorbent assays (4E6, DLH3 and E06) using murine monoclonal antibodies for determination of OxLDL blood levels have been developed. However, none of these assays are currently approved for routine clinical practice. We identified studies investigating OxLDL in CVD (measured by 4E6, DLH3 or E06 assay) by searching the PubMed database. Circulating OxLDL was found to be associated with all stages of atherosclerosis, from early atherogenesis to hypertension, coronary and peripheral arterial disease, acute coronary syndromes and ischemic cerebral infarction. The results of studies investigating the usefulness of OxLDL for CVD prediction were also summarized. Furthermore, OxLDL was found to be associated with pathologic conditions linked to CVD, including diabetes mellitus, obesity and metabolic syndrome (MetS). In addition, we have addressed the mechanisms by which OxLDL promotes atherogenesis, and the effects of antiatherogenic treatments on circulating OxLDL. Finally, we highlight the evidence suggesting that lipoprotein (a) [ Lp(a)] is the preferential carrier of oxidized phospholipids (OxPL) in human plasma. A strong association between OxPLapoB level (representing the content of OxPL on apolipoprotein B-100 particles, measured by E06 assay) and Lp(a) has been determined.en
dc.relationinfo:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173033/RS//
dc.relationinfo:eu-repo/grantAgreement/MESTD/Integrated and Interdisciplinary Research (IIR or III)/41002/RS//
dc.rightsrestrictedAccessen
dc.sourceCritical Reviews in Clinical Laboratory Sciencesen
dc.subjectAtherogenesisen
dc.subjectbiomarkeren
dc.subjectcardiovascular risk assessmenten
dc.subjectlipoprotein (a)en
dc.subjectoxidized lipoproteinsen
dc.subjectstatinsen
dc.titleOxidized low-density lipoprotein as a biomarker of cardiovascular diseasesen
dc.typereviewen
dc.rights.licenseARR
dcterms.abstractСтанимировић Јулијана; Радак, Дјордје; Ресановић Ивана; Исеновић Есма; Јевремовиц, Данимир; Цениц-Милосевиц, Десанка; Моуса, Схакер A.; Трпковиц, Aндреја;
dc.citation.volume52
dc.citation.issue2
dc.citation.spage70
dc.citation.epage85
dc.identifier.wos000357099600003
dc.identifier.doi10.3109/10408363.2014.992063
dc.citation.rankM21a
dc.identifier.pmid25537066
dc.type.versionpublishedVersion
dc.identifier.scopus2-s2.0-84930858928


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record